3/23/2009 10:00:24 AM
BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals (VGX), a developer of DNA vaccines and therapies against cancer and infectious diseases, announced today an agreement with the PATH Malaria Vaccine Initiative (MVI) to evaluate in a preclinical feasibility study VGX’s SynCon™ DNA vaccine development platform. More specifically, VGX will design and test DNA vaccine candidates using target antigens from Plasmodium species and deliver them intradermally using the CELLECTRA® constant current electroporation device. The collaboration brings together vaccine development and malaria experts from the University of Pennsylvania School of Medicine and VGX.
comments powered by